The pharmaceutical world is abuzz with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor medication expected to revolutionize the landscape to weight reduction . Preliminary clinical trials suggest this drug offers significant gains over current treatments, potentially contributing